Dear Reader,
We continuously strive to improve the content and design of Human Vaccines & Immunotherapeutics in order to make the journal as useful and attractive as possible for our readers. Starting with our current issue, the content will be organized by topic rather than by paper type. Regular submissions of all types (commentary, research paper, review, etc.) on a particular subject will be grouped and presented in one unit. This new concept will provide readers with a better overview of the contents of each issue, and help them to easily identify groups of papers published in a field of interest. For authors, this new concept offers greater visibility for their paper in that it will be picked up more often and easily in the context of related papers.
In this issue, we draw your attention to five contributions related to the topic of New Targets Also in this issue, we are pleased to present the US-based company ImmunoCellular Therapeutics (IMUC) in our monthly News, Policy and Profiles (NPP) section. The company develops multi-targeted cancer immunotherapies that aim to eliminate cancer stem cells in addition to normal bulk tumor cells. Dr John Yu, Interim CEO and President of IMUC, kindly agreed to answer our questions. If you would like to see your company/organization portrayed in Human Vaccines & Immunotherapeutics (HV&I), please contact the Acquisitions Editor Eva Riedmann (eva@landesbioscience.com). The NPP track is also an excellent platform to share your opinion on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. Suggestions for commentaries and opinion pieces are welcome. As always, the NPP track features a selection of the latest news related to vaccines and immunotherapeutics.
We realize that many scientists wish for free access to and distribution of published articles. Thus, HV&I offers a flexible open access (OA) model with highly competitive OA fees. The cost to make an original research paper OA is $750, $500 for reviews and for all other types of papers, the OA fee is $250. 
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